Supplemental file - Remdesivir Overview - PPA 2022 - SGVR.pdf (536.02 kB)
Download file

PPA-2021-0023 - Remdesivir Overview

Download (536.02 kB)
posted on 31.05.2022, 08:12 authored by Sandro G Viveiros Rosa, Wilson C. Santos

By December 2021, the COVID-19 caused approximately 6.1 million deaths around the world. Several

vaccines have been approved, but there is still a need for non-prophylactic treatments for COVID-19.

Remdesivir is an antiviral drug approved for emergency use against COVID-19 in several countries, but

one of the first clinical trials was inconclusive about the mortality reduction, although the drug showed a

reduction in the recovery time of hospitalized patients. Thus, the present investigation revisits the clinical

evidence of using remdesivir for COVID-19 treatment, patent status, pharmacology and chemistry. We

found 184 families of patents in the Cortellis database, and concerning the clinical evidence, we retrieved

14 systematic reviews with meta-analysis involving remdesivir as a treatment for COVID-19, discussing the

reduction of adverse events, hospitalization days, mortality rate and the mechanical ventilation period.